<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042041</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 08208</org_study_id>
    <secondary_id>NCI-2009-01488</secondary_id>
    <nct_id>NCT01042041</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer</brief_title>
  <official_title>A Phase 1 Study of Sorafenib Integrated With Chemoembolization for Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in&#xD;
      chemotherapy work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Chemoembolization kills tumor cells by blocking the&#xD;
      blood flow to the tumor and keeping chemotherapy drugs near the tumor.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying side effects and best dose of sorafenib tosylate when&#xD;
      given together with chemoembolization in treating patients with unresectable liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To evaluate the toxicity and safety of integrating sorafenib with chemoembolization for&#xD;
      unresectable hepatocellular carcinoma.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To observe the imaging response (AASLD/EASL modification of RECIST) and time to&#xD;
      progression following chemoembolization in conjunction with sorafenib.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients&#xD;
      undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C.&#xD;
&#xD;
      Chemoembolizaton repeats once a month for up to 4 procedures in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 3&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose adjustment, number and percentage of subjects with adverse events, laboratory changes, number and percentage of subjects with laboratory values that are outside the pre-determined ranges, cumulative toxicity, and TLT.</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver Cancer</condition>
  <condition>Localized Unresectable Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given via transarterial/hepatic chemoembolization</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>Adriblastina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given via transarterial/hepatic chemoembolization</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>PDD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
    <description>Given via transarterial/hepatic chemoembolization</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>MITC</other_name>
    <other_name>MITO</other_name>
    <other_name>MITO-C</other_name>
    <other_name>Mito-Medac</other_name>
    <other_name>Mitocin-C</other_name>
    <other_name>MTC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic artery embolization</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma&#xD;
&#xD;
          -  AND/OR Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) consistent&#xD;
             with liver cirrhosis AND at least one solid liver lesion &gt; 2cm with arterial-phase&#xD;
             enhancement and delayed washout regardless of alpha-feto protein levels (AFP)&#xD;
&#xD;
          -  AND/OR AFP &gt; 400ng/mL AND evidence of at least one solid liver lesion &gt; 2cm regardless&#xD;
             of specific imaging characteristics on CT or MRI&#xD;
&#xD;
          -  Patient is not a candidate for transplantation, resection, or ablation; for whom the&#xD;
             intended therapy is chemoembolization&#xD;
&#xD;
          -  Patient meets clinical criteria for treatment with chemoembolization&#xD;
&#xD;
          -  Absolute contraindications to chemoembolization include an uncorrectable bleeding&#xD;
             disorder, uncorrectable contrast sensitivity, leukopenia (white blood cell count &lt;&#xD;
             1000/uL), cardiac or renal insufficiency (serum creatinine &gt; 2.0mg/dL), hepatic&#xD;
             encephalopathy, jaundice, or dilated intrahepatic bile ducts&#xD;
&#xD;
          -  Portal vein occlusion is a relative contraindication and chemoembolization can be&#xD;
             performed only if there are collateral vessels with hepato-pedal flow demonstrated&#xD;
             angiographically&#xD;
&#xD;
          -  Hepatic compromise as determined by the following combination of parameters is a&#xD;
             contraindication to therapy: lactate dehydrogenase &gt; 425 U/L, aspartate&#xD;
             aminotransferase &gt; 100 U/L, total bilirubin &gt; 2.0 mg/dL and &gt; 50% liver volume&#xD;
             replaced by tumor&#xD;
&#xD;
          -  Patients may have been treated with ablation or resection in the past, but no sooner&#xD;
             than 4 weeks before study registration&#xD;
&#xD;
          -  Patients may NOT have been previously treated with sorafenib, chemoembolization,&#xD;
             radioembolization, or systemic chemotherapy with cytotoxic agents or molecularly&#xD;
             targeted agents&#xD;
&#xD;
          -  ECOG performance status =&lt; 2&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Platelets &gt;= 50,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 2.0 mg/dl&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) =&lt; 3X institutional upper limit of normal&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dl&#xD;
&#xD;
          -  INR =&lt; 1.5&#xD;
&#xD;
          -  Patients must have no clinical signs of heart failure and meet New York Heart&#xD;
             Association functional classification I or II defined as:&#xD;
&#xD;
        Class I - Patients with no limitation of activities; they suffer no symptoms from ordinary&#xD;
        activities; Class II - Patients with slight, mild limitation of activity; they are&#xD;
        comfortable with rest or with mild exertion&#xD;
&#xD;
          -  Because agents used in this trial are known to be teratogenic, women of child-bearing&#xD;
             potential and men must agree to use adequate contraception (hormonal or barrier method&#xD;
             of birth control; abstinence) prior to study entry and for the duration of study&#xD;
             participation&#xD;
&#xD;
          -  Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her treating physician immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to sorafenib&#xD;
&#xD;
          -  History of radiologic contrast reactions not controlled by standard premedications&#xD;
&#xD;
          -  Patients must not be taking cytochrome P450 enzyme inducing drugs&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, uncontrolled hypertension, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study&#xD;
&#xD;
          -  Breastfeeding should be discontinued&#xD;
&#xD;
          -  Prophylactic use of G-CSF or GM-CSF is not permitted on this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Soulen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 10, 2009</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2013</last_update_posted>
  <responsible_party>
    <name_title>Soulen, Michael</name_title>
    <organization>Abramson Cancer Center of The University of Pennsylvania</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

